ライム病ワクチン市場レポート：動向、予測、競合分析 (2031年まで)

世界のライム病ワクチン市場の将来性は有望で、病院や臨床検査室市場に機会があります。ライム病ワクチン市場は、2025年から2031年にかけてCAGR 8.1%で成長すると予想されています。この市場の主な促進要因は、新興の媒介性疾患の増加、政府の取り組みとイニシアティブの拡大、公衆衛生教育と啓発キャンペーンの増加です。

• Lucintel社の予測では、技術別では、感度が高く、適用範囲が広いリンパ球性形質転換検査が予測期間中に高い成長を遂げる見込みです。
• 最終用途別ではでは、病院は患者数が多く、多様なサービスを提供しているため、より高い成長が見込まれます。
• 地域別では、北米は医療の先進国であり、インフラも整っていることから、予測期間中に最も高い成長が見込まれます。

ライム病ワクチン市場の新たな動向

ライム病ワクチン市場は、技術の進歩から公衆衛生戦略の変化まで、様々な世界の動向によって急速に発展しています。このような動向は、ライム病への対応方法を再構築し、ワクチン開発者や公衆衛生機関に新たな機会を提供しています。

• ワクチン研究開発への再注力：2002年のLYMErixの撤退後、ライム病ワクチン開発に再び焦点が当てられています。研究者たちは、mRNAや組換えDNAなどの先端技術を用いた新しいワクチン候補を模索しています。これらの新しいワクチンは、安全性の問題や有効性など、これまでの候補の欠点を克服することを目的としています。ライム病の罹患率の増加に伴い、このような努力は勢いを増しており、複数のワクチンが臨床試験に入っています。この動向は、ライム病対策における長期的な解決策への前向きな転換を意味します。
• 媒介感染症ワクチンへの需要の高まり：気候変動がマダニの生息分布に影響を及ぼす中、ライム病のような媒介感染症を予防するワクチンの需要が高まっています。マダニの世界的な広がり、特にこれまでライム病が知られていなかった地域での広がりは、ワクチン接種戦略への幅広いニーズを生み出しています。政府や保健機関は、ライム病が重要な部分を占める、より広範なダニ媒介性疾患に注目しています。この動向は、これらの疾患を制御し、新たな地域での大規模な発生を予防するためのワクチンの緊急性を強調しています。
• グローバルなワクチン共同開発：製薬会社、学術機関、政府間の共同研究は、ライム病ワクチン市場における重要な動向です。ライム病は世界的に重要な問題であるため、調査活動はますます国際的になってきています。米国やドイツなどライム病罹患率の高い国々は、知識、資源、臨床試験データを共有するために協力しています。このような協力的なアプローチは、ワクチンの開発と流通を促進し、ライム病の世界的な増加に対するより協調的な対応を確実なものにしています。
• 公衆衛生教育と啓発キャンペーン公衆衛生教育は、ライム病ワクチンプログラムの成功に不可欠です。ライム病は診断も治療も困難であるため、教育キャンペーンはマダニに咬まれる予防、ライム病の症状、ワクチン接種の重要性についての認識を高めています。これらのキャンペーンは、ワクチン接種へのためらいを解消し、予防対策の重要性を広めることを目的としています。一般市民の意識が高まるにつれ、ワクチンの接種率は上昇し、ライム病ワクチンの持続可能な市場開拓を後押しすると期待されています。
• ライム病ワクチンの定期予防接種プログラムへの組み入れ：ライム病ワクチンが広く利用されるようになれば、定期予防接種プログラムへの統合が重要な動向となります。この統合により、特にライム病が流行している地域では、ワクチン接種が公衆衛生活動の標準的な一部となります。小児期の予防接種スケジュールにライム病ワクチンが組み込まれることで、接種率が向上し、罹患率が減少する可能性があります。このような動向は、ライム病予防の普及とワクチン戦略の長期的な成功にとって極めて重要です。

このような新たな動向は、ワクチン接種によるライム病予防への関心の高まりを反映しています。ワクチン開発における技術的進歩から、一般市民の意識の向上、世界の協力体制に至るまで、これらの動向はライム病ワクチン市場が前向きな軌道にあることを示しています。このような変化はワクチン開発を加速させ、公衆衛生上の成果を改善し、ライム病の世界的な負担を軽減することが期待されます。

ライム病ワクチン市場の最近の動向

ライム病ワクチン市場における最近の動向は、予防戦略の展望を形作るものであり、ライム病の制圧にますます焦点が当てられていることを示しています。以下の主な発展は、現在の市場の方向性を浮き彫りにしています。

• 新規ライム病ワクチン候補の開発：いくつかの製薬会社が新しいライム病ワクチンの研究段階に入り、mRNAや組換えタンパク質のような革新的技術を用いた有望な候補が登場しています。これらのワクチンは、安全性の改善、有効性の向上、幅広い防御を目的としています。現在、複数のワクチン候補が臨床試験段階にあり、今後数年のうちに新たなワクチンの波が押し寄せる可能性を示しています。
• ライム病ワクチン研究パートナーシップ：製薬企業と研究機関の共同開発は、ライム病ワクチン開発を加速させています。その顕著な例が、より効果的なライム病ワクチンの開発を目的とした米国企業と学術機関との提携です。このような協力関係は、より良い資源配分と迅速なワクチン開発を可能にし、ライム病罹患率の減少に向けた世界的な取り組みに貢献しています。
• ライム病ワクチン研究への資金提供の拡大：米国やドイツなどの各国政府は、マダニが媒介する感染症による公衆衛生の脅威が増大していることを認識し、ライム病ワクチン研究への資金提供を拡大しています。この資金援助は、臨床試験や新しいワクチンの開発に役立っています。ライム病患者の増加に伴い、ワクチン研究への資源配分は増加し、効果的なワクチンの迅速な開発が期待されています。
• ライム病に対する世界的な認識の高まり：これまで感染者がいなかった地域でライム病患者が増加していることから、ライム病とその公衆衛生への影響に対する認識が高まっています。世界保健機関（WHO）やCDCのような組織はダニ媒介性疾患に対する認識を促進し、ライム病ワクチンへの関心を高めています。このような関心の変化により、予防対策やワクチンに対する需要も高まっています。
• 複数のダニ媒介性疾患に対するワクチンの開発：ダニ媒介性疾患の増加により、複数の病原体を標的としたワクチンの開発が進んでいます。ライム病、ダニ媒介性脳炎、その他のダニ媒介性疾患を予防できるワクチンを調査している企業もあります。このようなマルチターゲットワクチンは、包括的な防御の可能性を提供し、様々なダニ媒介性疾患の影響を受ける地域における公衆衛生活動を改善します。

ライム病ワクチン市場の最近の動向は、ワクチン研究、パートナーシップ、社会的認知の著しい進歩を示しています。このような取り組みにより、ライム病やその他のダニ媒介性疾患による世界的な負担が軽減され、予防の新たな機会が提供され、世界的に公衆衛生上の成果が向上すると期待されています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界のライム病ワクチン市場：技術別

• 概要
• 魅力分析：技術別
• リンパ球性転換試験：動向と予測（2019～2031年）
• 尿抗原検査：動向と予測（2019～2031年）
• 免疫蛍光染色核酸検査：動向と予測（2019～2031年）
• 血清学的検査：動向と予測（2019～2031年）

第5章 世界のライム病ワクチン市場：最終用途別

• 概要
• 魅力分析：最終用途別
• 病院：動向と予測（2019～2031年）
• 臨床検査室：動向と予測（2019～2031年）
• その他：動向と予測（2019-2031）

第6章 地域分析

• 概要
• 世界のライム病ワクチン市場：地域別

第7章 北米のライム病ワクチン市場

• 概要
• 北米のライム病ワクチン市場：技術別
• 北米のライム病ワクチン市場：最終用途別
• 米国のライム病ワクチン市場
• メキシコのライム病ワクチン市場
• カナダのライム病ワクチン市場

第8章 欧州のライム病ワクチン市場

• 概要
• 欧州のライム病ワクチン市場：技術別
• 欧州のライム病ワクチン市場：最終用途別
• ドイツのライム病ワクチン市場
• フランスのライム病ワクチン市場
• スペインライム病ワクチン市場
• イタリアのライム病ワクチン市場
• 英国のライム病ワクチン市場

第9章 アジア太平洋のライム病ワクチン市場

• 概要
• アジア太平洋のライム病ワクチン市場：技術別
• アジア太平洋のライム病ワクチン市場：最終用途別
• 日本のライム病ワクチン市場
• インドのライム病ワクチン市場
• 中国のライム病ワクチン市場
• 韓国のライム病ワクチン市場
• インドネシアのライム病ワクチン市場

第10章 その他の地域 (ROW) のライム病ワクチン市場

• 概要
• その他の地域 (ROW) のライム病ワクチン市場：技術別
• その他の地域 (ROW) のライム病ワクチン市場：最終用途別
• 中東のライム病ワクチン市場
• 南米のライム病ワクチン市場
• アフリカのライム病ワクチン市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • 成長機会：技術別
  • 成長機会：最終用途別
• 世界のライム病ワクチン市場の新たな動向
• 戦略分析
  • 新製品開発
  • 認証・ライセンシング
  • 企業合併・買収 (M&A) 、契約、提携、合弁事業

第13章 バリューチェーン上の主要企業のプロファイル

• Competitive Analysis
• T2 Biosystems
• Bio-Rad Laboratories
• Oxford Immunotec USA
• ROCHE DIAGNOSTICS INTERNATIONAL LTD
• Abbott

第14章 付録

• 図の一覧
• 表の一覧
• 分析手法
• 免責事項
• 著作権
• 略語と技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Lyme Disease Vaccine Market
• Figure 2.1: Usage of Lyme Disease Vaccine Market
• Figure 2.2: Classification of the Global Lyme Disease Vaccine Market
• Figure 2.3: Supply Chain of the Global Lyme Disease Vaccine Market
• Figure 2.4: Driver and Challenges of the Lyme Disease Vaccine Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Lyme Disease Vaccine Market by Technology in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Lyme Disease Vaccine Market ($B) by Technology
• Figure 4.3: Forecast for the Global Lyme Disease Vaccine Market ($B) by Technology
• Figure 4.4: Trends and Forecast for Lymphocytic Transformation Test in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 4.5: Trends and Forecast for Urine Antigen Testing in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 4.6: Trends and Forecast for Immunofluorescent Staining Nucleic acid Test in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 4.7: Trends and Forecast for Serological Test in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 5.1: Global Lyme Disease Vaccine Market by End Use in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Lyme Disease Vaccine Market ($B) by End Use
• Figure 5.3: Forecast for the Global Lyme Disease Vaccine Market ($B) by End Use
• Figure 5.4: Trends and Forecast for Hospitals in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 5.5: Trends and Forecast for Clinical Laboratories in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 5.6: Trends and Forecast for Others in the Global Lyme Disease Vaccine Market (2019-2031)
• Figure 6.1: Trends of the Global Lyme Disease Vaccine Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Lyme Disease Vaccine Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Lyme Disease Vaccine Market (2019-2031)
• Figure 7.2: North American Lyme Disease Vaccine Market by Technology in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Lyme Disease Vaccine Market ($B) by Technology (2019-2024)
• Figure 7.4: Forecast for the North American Lyme Disease Vaccine Market ($B) by Technology (2025-2031)
• Figure 7.5: North American Lyme Disease Vaccine Market by End Use in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Lyme Disease Vaccine Market ($B) by End Use (2019-2024)
• Figure 7.7: Forecast for the North American Lyme Disease Vaccine Market ($B) by End Use (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Lyme Disease Vaccine Market (2019-2031)
• Figure 8.2: European Lyme Disease Vaccine Market by Technology in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Lyme Disease Vaccine Market ($B) by Technology (2019-2024)
• Figure 8.4: Forecast for the European Lyme Disease Vaccine Market ($B) by Technology (2025-2031)
• Figure 8.5: European Lyme Disease Vaccine Market by End Use in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Lyme Disease Vaccine Market ($B) by End Use (2019-2024)
• Figure 8.7: Forecast for the European Lyme Disease Vaccine Market ($B) by End Use (2025-2031)
• Figure 8.8: Trends and Forecast for the German Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Lyme Disease Vaccine Market (2019-2031)
• Figure 9.2: APAC Lyme Disease Vaccine Market by Technology in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Lyme Disease Vaccine Market ($B) by Technology (2019-2024)
• Figure 9.4: Forecast for the APAC Lyme Disease Vaccine Market ($B) by Technology (2025-2031)
• Figure 9.5: APAC Lyme Disease Vaccine Market by End Use in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Lyme Disease Vaccine Market ($B) by End Use (2019-2024)
• Figure 9.7: Forecast for the APAC Lyme Disease Vaccine Market ($B) by End Use (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Lyme Disease Vaccine Market (2019-2031)
• Figure 10.2: ROW Lyme Disease Vaccine Market by Technology in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Lyme Disease Vaccine Market ($B) by Technology (2019-2024)
• Figure 10.4: Forecast for the ROW Lyme Disease Vaccine Market ($B) by Technology (2025-2031)
• Figure 10.5: ROW Lyme Disease Vaccine Market by End Use in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Lyme Disease Vaccine Market ($B) by End Use (2019-2024)
• Figure 10.7: Forecast for the ROW Lyme Disease Vaccine Market ($B) by End Use (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Lyme Disease Vaccine Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Lyme Disease Vaccine Market
• Figure 11.2: Market Share (%) of Top Players in the Global Lyme Disease Vaccine Market (2024)
• Figure 12.1: Growth Opportunities for the Global Lyme Disease Vaccine Market by Technology
• Figure 12.2: Growth Opportunities for the Global Lyme Disease Vaccine Market by End Use
• Figure 12.3: Growth Opportunities for the Global Lyme Disease Vaccine Market by Region
• Figure 12.4: Emerging Trends in the Global Lyme Disease Vaccine Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Lyme Disease Vaccine Market by Technology and End Use
• Table 1.2: Attractiveness Analysis for the Lyme Disease Vaccine Market by Region
• Table 1.3: Global Lyme Disease Vaccine Market Parameters and Attributes
• Table 3.1: Trends of the Global Lyme Disease Vaccine Market (2019-2024)
• Table 3.2: Forecast for the Global Lyme Disease Vaccine Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Lyme Disease Vaccine Market by Technology
• Table 4.2: Market Size and CAGR of Various Technology in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Technology in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 4.4: Trends of Lymphocytic Transformation Test in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 4.5: Forecast for Lymphocytic Transformation Test in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 4.6: Trends of Urine Antigen Testing in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 4.7: Forecast for Urine Antigen Testing in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 4.8: Trends of Immunofluorescent Staining Nucleic acid Test in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 4.9: Forecast for Immunofluorescent Staining Nucleic acid Test in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 4.10: Trends of Serological Test in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 4.11: Forecast for Serological Test in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Lyme Disease Vaccine Market by End Use
• Table 5.2: Market Size and CAGR of Various End Use in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various End Use in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 5.4: Trends of Hospitals in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 5.5: Forecast for Hospitals in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 5.6: Trends of Clinical Laboratories in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 5.7: Forecast for Clinical Laboratories in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 5.8: Trends of Others in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 5.9: Forecast for Others in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Lyme Disease Vaccine Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Lyme Disease Vaccine Market (2025-2031)
• Table 7.1: Trends of the North American Lyme Disease Vaccine Market (2019-2024)
• Table 7.2: Forecast for the North American Lyme Disease Vaccine Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Technology in the North American Lyme Disease Vaccine Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Technology in the North American Lyme Disease Vaccine Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various End Use in the North American Lyme Disease Vaccine Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various End Use in the North American Lyme Disease Vaccine Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Lyme Disease Vaccine Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Lyme Disease Vaccine Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Lyme Disease Vaccine Market (2019-2031)
• Table 8.1: Trends of the European Lyme Disease Vaccine Market (2019-2024)
• Table 8.2: Forecast for the European Lyme Disease Vaccine Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Technology in the European Lyme Disease Vaccine Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Technology in the European Lyme Disease Vaccine Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various End Use in the European Lyme Disease Vaccine Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various End Use in the European Lyme Disease Vaccine Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Lyme Disease Vaccine Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Lyme Disease Vaccine Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Lyme Disease Vaccine Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Lyme Disease Vaccine Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Lyme Disease Vaccine Market (2019-2031)
• Table 9.1: Trends of the APAC Lyme Disease Vaccine Market (2019-2024)
• Table 9.2: Forecast for the APAC Lyme Disease Vaccine Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Technology in the APAC Lyme Disease Vaccine Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Technology in the APAC Lyme Disease Vaccine Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various End Use in the APAC Lyme Disease Vaccine Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various End Use in the APAC Lyme Disease Vaccine Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Lyme Disease Vaccine Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Lyme Disease Vaccine Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Lyme Disease Vaccine Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Lyme Disease Vaccine Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Lyme Disease Vaccine Market (2019-2031)
• Table 10.1: Trends of the ROW Lyme Disease Vaccine Market (2019-2024)
• Table 10.2: Forecast for the ROW Lyme Disease Vaccine Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Technology in the ROW Lyme Disease Vaccine Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Technology in the ROW Lyme Disease Vaccine Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various End Use in the ROW Lyme Disease Vaccine Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various End Use in the ROW Lyme Disease Vaccine Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Lyme Disease Vaccine Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Lyme Disease Vaccine Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Lyme Disease Vaccine Market (2019-2031)
• Table 11.1: Product Mapping of Lyme Disease Vaccine Suppliers Based on Segments
• Table 11.2: Operational Integration of Lyme Disease Vaccine Manufacturers
• Table 11.3: Rankings of Suppliers Based on Lyme Disease Vaccine Revenue
• Table 12.1: New Product Launches by Major Lyme Disease Vaccine Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Lyme Disease Vaccine Market

The future of the global Lyme disease vaccine market looks promising with opportunities in the markets. The Lyme disease vaccine market is expected to grow with a CAGR of 8.1% from 2025 to 2031. The major drivers for this market are the increasing occurrences of emerging vector-borne diseases, the expanding government efforts and initiatives, and the increasing public health education and awareness campaigns.

• Lucintel forecasts that, within the technology category, lymphocytic transformation test is expected to witness higher growth over the forecast period due to higher sensitivity, broader applicability.
• Within the end-use category, hospitals are expected to witness higher growth due to larger patient volume, diverse services.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to advanced healthcare, strong infrastructure.

Emerging Trends in the Lyme Disease Vaccine Market

The Lyme disease vaccine market is evolving rapidly, driven by various global trends, from technological advancements to changes in public health strategies. These trends are reshaping how Lyme disease is addressed and providing new opportunities for vaccine developers and public health organizations.

• Renewed focus on vaccine research and development: After the withdrawal of LYMErix in 2002, there has been a renewed focus on Lyme disease vaccine development. Researchers are exploring new vaccine candidates using advanced technologies such as mRNA and recombinant DNA. These new vaccines aim to overcome the shortcomings of previous candidates, including safety concerns and efficacy. With increasing Lyme disease incidence, these efforts are gaining momentum, with multiple vaccines entering clinical trials. This trend signifies a positive shift toward long-term solutions in combating Lyme disease.
• Growing demand for vector-borne disease vaccines: As climate change influences the distribution of tick populations, the demand for vaccines to prevent vector-borne diseases like Lyme disease is increasing. The global spread of ticks, especially in areas not previously known for Lyme disease, has created a wider need for vaccination strategies. Governments and health organizations are focusing on the broader category of tick-borne diseases, of which Lyme disease is a significant part. This trend emphasizes the urgency for vaccines to control these diseases and prevent larger outbreaks in new areas.
• Collaborative global vaccine development: Collaboration between pharmaceutical companies, academic institutions, and governments is a key trend in the Lyme disease vaccine market. With Lyme disease being a significant global concern, research efforts are increasingly international. Countries with high Lyme disease rates, such as the United States and Germany, are working together to share knowledge, resources, and clinical trial data. This collaborative approach helps accelerate the development and distribution of vaccines, ensuring a more coordinated response to the global rise in Lyme disease.
• Public health education and awareness campaigns: Public health education is critical to the success of any Lyme disease vaccine program. With Lyme disease being difficult to diagnose and treat, educational campaigns are raising awareness about tick bite prevention, the symptoms of Lyme disease, and the importance of vaccination. These campaigns aim to address vaccine hesitancy and promote the importance of preventative measures. As public awareness grows, vaccine uptake is expected to rise, supporting the development of a sustainable market for Lyme disease vaccines.
• Integration of Lyme disease vaccines into routine immunization programs: Once a Lyme disease vaccine becomes widely available, integrating it into routine immunization programs is seen as a key trend. This integration would make vaccination a standard part of public health efforts, especially in areas where Lyme disease is prevalent. The inclusion of Lyme disease vaccines in childhood immunization schedules could increase coverage and reduce disease incidence. This trend is crucial for ensuring widespread protection and the long-term success of vaccine strategies.

These emerging trends reflect the growing focus on preventing Lyme disease through vaccination. From technological advancements in vaccine development to increased public awareness and global collaboration, these trends indicate that the Lyme disease vaccine market is on a positive trajectory. These shifts are expected to accelerate vaccine development, improve public health outcomes, and reduce the global burden of Lyme disease.

Recent Developments in the Lyme Disease Vaccine Market

Recent developments in the Lyme disease vaccine market are shaping the landscape of prevention strategies and are indicative of the increasing focus on controlling the disease. The following key developments highlight the current direction of the market.

• Advancement of new Lyme disease vaccine candidates: Several pharmaceutical companies have entered the research phase for new Lyme disease vaccines, with promising candidates using innovative technologies like mRNA and recombinant proteins. These vaccines aim to offer improved safety profiles, greater efficacy, and broader protection. Multiple vaccine candidates are currently in clinical trials, signaling the potential for a new wave of vaccines in the coming years.
• Lyme disease vaccine research partnerships: Collaboration between pharmaceutical companies and research institutions is accelerating Lyme disease vaccine development. A notable example is the partnership between U.S.-based companies and academic institutions to develop more effective Lyme disease vaccines. These collaborations allow for better resource allocation and faster vaccine development, contributing to global efforts to reduce Lyme disease incidence.
• Expanded funding for Lyme disease vaccine research: Governments in countries like the United States and Germany have increased funding for Lyme disease vaccine research, recognizing the growing public health threat posed by tick-borne diseases. This funding is helping support clinical trials and the development of new vaccines. As Lyme disease cases rise, the allocation of resources to vaccine research is expected to grow, ensuring the swift development of effective vaccines.
• Increased global awareness of Lyme disease: The rising number of Lyme disease cases in previously unaffected regions has led to increased awareness of the disease and its impact on public health. Organizations like the World Health Organization (WHO) and the CDC are promoting tick-borne disease awareness, which has generated interest in Lyme disease vaccines. This shift in focus has also increased the demand for prevention measures and vaccines.
• Development of vaccines for multiple tick-borne diseases: The increasing number of tick-borne diseases has led to the development of vaccines targeting multiple pathogens. Some companies are researching vaccines that can protect against Lyme disease, tick-borne encephalitis, and other tick-borne illnesses. These multi-target vaccines offer the potential for comprehensive protection, improving public health efforts in areas affected by various tick-borne diseases.

Recent developments in the Lyme disease vaccine market show significant progress in vaccine research, partnerships, and public awareness. These efforts are expected to reduce the global burden of Lyme disease and other tick-borne illnesses, offering new opportunities for prevention and improving public health outcomes worldwide.

Strategic Growth Opportunities in the Lyme Disease Vaccine Market

The Lyme disease vaccine market presents multiple strategic growth opportunities across various applications. These opportunities are expected to drive innovation, improve vaccine access, and contribute to the overall reduction of Lyme disease cases globally.

• Expanding vaccine access in endemic regions: There is a major opportunity to expand Lyme disease vaccine access in areas with high tick populations, such as the northeastern United States and parts of Europe. Government-backed programs and partnerships with healthcare providers can help ensure that vaccines reach at-risk populations, particularly in rural and underserved areas. Increasing access to vaccines will be key to controlling the spread of Lyme disease.
• Collaboration with public health organizations: Collaborating with global health organizations like the WHO and the CDC can accelerate vaccine distribution and implementation. These partnerships can help streamline regulatory approval processes and ensure vaccines are available in countries with the highest burden of Lyme disease. Collaboration can also facilitate the sharing of research and clinical data to improve vaccine efficacy and safety.
• Incorporation of Lyme disease vaccines in travel health: With increasing international travel, there is an opportunity to integrate Lyme disease vaccines into travel health programs, particularly for individuals traveling to areas with a high prevalence of Lyme disease. This would help prevent the spread of the disease to new regions and protect travelers from infection.
• Development of combination vaccines: The development of combination vaccines that protect against multiple tick-borne diseases, such as Lyme disease, tick-borne encephalitis, and babesiosis, is a growing opportunity. This would streamline vaccination schedules and increase vaccine uptake, providing comprehensive protection against tick-borne diseases.
• Focus on pediatric vaccination programs: Implementing Lyme disease vaccines into routine pediatric immunization schedules offers a significant growth opportunity. As Lyme disease affects children in many endemic areas, vaccinating children at an early age would be an effective prevention strategy, ensuring long-term protection and reducing the disease burden in younger populations.

The Lyme disease vaccine market holds significant growth opportunities, ranging from expanding access in endemic regions to developing combination vaccines. By addressing these opportunities, stakeholders can improve vaccine access, reduce the global impact of Lyme disease, and ensure better public health outcomes.

Lyme Disease Vaccine Market Driver and Challenges

The Lyme disease vaccine market is influenced by several key drivers and challenges, which include technological advancements, economic factors, and regulatory hurdles. These factors play a crucial role in shaping the development, approval, and distribution of Lyme disease vaccines. Technological innovation, particularly in vaccine development, has significantly advanced over recent years. However, challenges related to vaccine acceptance, regulatory approval processes, and economic considerations remain substantial. As the market continues to evolve, understanding these drivers and challenges is essential for shaping strategies to improve vaccine access, effectiveness, and distribution.

The factors responsible for driving the Lyme disease vaccine market include:

1. Rising incidence of Lyme disease: The increasing number of Lyme disease cases, particularly in regions where it was previously less common, is a major driver for the Lyme disease vaccine market. As more individuals are affected by the disease, there is heightened awareness of the need for preventive measures. The rising incidence is particularly evident in the United States and Europe, where tick populations have expanded due to climate change. This growing public health concern underscores the need for vaccines that can reduce the burden of Lyme disease and limit the spread of the disease, driving demand for vaccine development.

2. Technological advancements in vaccine development: Recent technological innovations in vaccine research, such as mRNA technology and recombinant DNA technology, have made the development of Lyme disease vaccines more feasible and efficient. These advanced technologies offer improved safety profiles and higher efficacy rates compared to previous vaccine candidates. With these advancements, the Lyme disease vaccine market has gained momentum, as pharmaceutical companies are able to create more effective vaccines. Additionally, the ability to rapidly adapt to emerging disease variants through mRNA vaccines can provide quicker responses to Lyme disease outbreaks, further fueling market growth.

3. Increased public and government awareness: Governments and public health organizations are increasingly recognizing Lyme disease as a significant threat, leading to greater investments in prevention and vaccine research. In countries like the U.S. and Germany, the CDC and other health agencies have launched educational campaigns about Lyme disease, increasing awareness and driving demand for vaccines. As awareness rises, public support for vaccination programs also grows, making it easier for companies to gain funding and approval for their vaccine candidates. This trend is essential for ensuring the availability and widespread adoption of Lyme disease vaccines.

4. Advancements in tick-borne disease research: The growing body of research into tick-borne diseases and their mechanisms has led to better understanding of Lyme disease and how it can be prevented. As research advances, the development of multi-pathogen vaccines that target not just Lyme disease but other tick-borne diseases, such as babesiosis and anaplasmosis, becomes more viable. This research-focused environment encourages the development of innovative vaccines, attracting more funding and scientific attention to the Lyme disease vaccine market, further accelerating progress in vaccine development.

5. Public health policy and infrastructure investment: Increased investments by governments into public health infrastructure, particularly in areas with high Lyme disease prevalence, support the growth of the vaccine market. As healthcare systems focus on preventive care, Lyme disease vaccines are seen as a critical tool in reducing healthcare costs associated with treating Lyme disease. Government funding, combined with expanded healthcare access, creates an environment conducive to the development and distribution of vaccines. This trend is expected to continue as policymakers prioritize disease prevention and seek to reduce the long-term healthcare burden.

Challenges in the Lyme Disease Vaccine Market are:

1. Vaccine hesitancy and acceptance: One of the major challenges facing the Lyme disease vaccine market is vaccine hesitancy, which is influenced by public skepticism, misinformation, and concerns about vaccine safety. Despite the growing awareness of Lyme disease, many individuals are still hesitant to receive the vaccine due to fear of side effects or mistrust of pharmaceutical companies. Overcoming this hesitancy will require extensive public education campaigns to highlight the benefits of vaccination and address concerns. Failure to address vaccine hesitancy could limit the effectiveness and adoption of Lyme disease vaccines.

2. Regulatory hurdles and approval delays: The process of obtaining regulatory approval for new vaccines is lengthy and complex, which presents a significant challenge for the Lyme disease vaccine market. Stringent safety and efficacy standards must be met, and extensive clinical trials are required, which can delay the availability of vaccines. In addition, varying regulatory standards across different countries add complexity to the approval process. Delays in approval can slow down the widespread adoption of Lyme disease vaccines, limiting their impact on public health in the short term.

3. High development and production costs: The costs associated with developing and producing Lyme disease vaccines can be prohibitively high. Vaccine development requires significant investment in research, clinical trials, and manufacturing, which can deter smaller companies from entering the market. Additionally, scaling up production to meet demand requires considerable resources. The high costs may limit the availability of the vaccine in low-income regions, further exacerbating health disparities. Overcoming these economic challenges is critical to ensuring that Lyme disease vaccines are accessible to all populations, particularly in endemic areas.

The Lyme disease vaccine market is shaped by a mix of drivers and challenges. While rising disease incidence, technological advancements, and increasing public awareness are fueling growth, challenges such as vaccine hesitancy, regulatory hurdles, and high development costs threaten to slow progress. The success of this market will depend on overcoming these obstacles through effective public health strategies, efficient regulatory processes, and investments in vaccine production. By addressing these challenges and leveraging the market drivers, the Lyme disease vaccine market can play a key role in preventing the spread of Lyme disease and improving global health outcomes.

List of Lyme Disease Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, Lyme disease vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Lyme disease vaccine companies profiled in this report include:

• T2 Biosystems
• Bio-Rad Laboratories
• Oxford Immunotec USA
• ROCHE DIAGNOSTICS INTERNATIONAL LTD
• Abbott

Lyme Disease Vaccine Market by Segment

The study includes a forecast for the global Lyme disease vaccine market by technology, end use, and region.

Lyme Disease Vaccine Market by Technology [Value from 2019 to 2031]:

• Lymphocytic Transformation Test
• Urine Antigen Testing
• Immunofluorescent Staining Nucleic Acid Test
• Serological Test

Lyme Disease Vaccine Market by End Use [Value from 2019 to 2031]:

• Hospitals
• Clinical Laboratories
• Others

Lyme Disease Vaccine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lyme Disease Vaccine Market

The Lyme disease vaccine market has seen increasing attention due to the rising incidence of Lyme disease, which is transmitted through tick bites and can lead to serious health issues if left untreated. Recent developments in this market across key countries, including the United States, China, Germany, India, and Japan, have been driven by both the increasing awareness of Lyme disease and advancements in vaccine research. These regions are witnessing significant progress in vaccine development, approval, and distribution, aiming to combat the disease more effectively and ensure better protection for populations at risk.

• United States: In the United States, Lyme disease remains a significant public health concern, particularly in the northeastern and upper midwestern regions. Recent developments include the ongoing research and potential reintroduction of Lyme disease vaccines, following the withdrawal of LYMErix in the early 2000s. With the rise in Lyme disease cases, both public and private entities are investing in vaccine research, with promising candidates currently in clinical trials. Additionally, the CDC has ramped up its educational campaigns regarding tick-borne diseases, and efforts to address vaccine hesitancy have grown as part of broader public health initiatives.
• China: In China, Lyme disease is increasingly recognized as an emerging infectious disease, particularly in rural areas where people are more likely to come into contact with ticks. The Chinese government has begun funding research into Lyme disease vaccines, and initial studies are showing promise. China's focus on public health infrastructure and the growing awareness of zoonotic diseases have led to increased investments in tick control and Lyme disease prevention. Additionally, Chinese pharmaceutical companies are working on domestic vaccine production to address this growing health threat, although widespread vaccine distribution is still in the early stages.
• Germany: Germany has seen steady advancements in the Lyme disease vaccine market, although there has not yet been a significant push for a national vaccine rollout. Lyme disease cases in Germany have risen, especially in the southern and eastern regions. The country has increased its investment in Lyme disease research, with efforts focused on understanding the full range of symptoms and the efficacy of potential vaccines. While Germany does not yet have an approved Lyme disease vaccine, there is considerable interest in collaboration with European Union research initiatives to develop and distribute a vaccine in the future.
• India: India has been facing an increasing incidence of vector-borne diseases, including Lyme disease, due to expanding tick populations. Research into vaccines for Lyme disease is in its early stages, with most efforts concentrated in academic and research institutions. India's government has been focusing on controlling tick-borne diseases more generally, which includes exploring vaccines for Lyme disease. While vaccine development has not yet reached the commercial stage, the growing recognition of Lyme disease and its health implications is expected to drive further research and development efforts in the coming years.
• Japan: Japan has a low but increasing number of Lyme disease cases, mainly in rural areas where tick populations are more prominent. Japanese health authorities have initiated research into Lyme disease vaccines as part of broader efforts to combat vector-borne diseases. Japan's highly advanced healthcare infrastructure and strong pharmaceutical industry place it in a favorable position to develop and distribute a Lyme disease vaccine. However, there is still a need for greater public awareness of Lyme disease and its prevention to increase vaccine acceptance once available. Research and collaboration with global health organizations are seen as key to future vaccine success.

Features of the Global Lyme Disease Vaccine Market

• Market Size Estimates: Lyme disease vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Lyme disease vaccine market size by technology, end use, and region in terms of value ($B).
• Regional Analysis: Lyme disease vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different technology, end use, and regions for the Lyme disease vaccine market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the Lyme disease vaccine market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Lyme disease vaccine market by technology (lymphocytic transformation test, urine antigen testing, immunofluorescent staining nucleic acid test, and serological test), end use (hospitals, clinical laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Lyme Disease Vaccine Market by Technology

• 4.1 Overview
• 4.2 Attractiveness Analysis by Technology
• 4.3 Lymphocytic Transformation Test: Trends and Forecast (2019-2031)
• 4.4 Urine Antigen Testing: Trends and Forecast (2019-2031)
• 4.5 Immunofluorescent Staining Nucleic acid Test: Trends and Forecast (2019-2031)
• 4.6 Serological Test: Trends and Forecast (2019-2031)

5. Global Lyme Disease Vaccine Market by End Use

• 5.1 Overview
• 5.2 Attractiveness Analysis by End Use
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Clinical Laboratories: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Lyme Disease Vaccine Market by Region

7. North American Lyme Disease Vaccine Market

• 7.1 Overview
• 7.2 North American Lyme Disease Vaccine Market by Technology
• 7.3 North American Lyme Disease Vaccine Market by End Use
• 7.4 United States Lyme Disease Vaccine Market
• 7.5 Mexican Lyme Disease Vaccine Market
• 7.6 Canadian Lyme Disease Vaccine Market

8. European Lyme Disease Vaccine Market

• 8.1 Overview
• 8.2 European Lyme Disease Vaccine Market by Technology
• 8.3 European Lyme Disease Vaccine Market by End Use
• 8.4 German Lyme Disease Vaccine Market
• 8.5 French Lyme Disease Vaccine Market
• 8.6 Spanish Lyme Disease Vaccine Market
• 8.7 Italian Lyme Disease Vaccine Market
• 8.8 United Kingdom Lyme Disease Vaccine Market

9. APAC Lyme Disease Vaccine Market

• 9.1 Overview
• 9.2 APAC Lyme Disease Vaccine Market by Technology
• 9.3 APAC Lyme Disease Vaccine Market by End Use
• 9.4 Japanese Lyme Disease Vaccine Market
• 9.5 Indian Lyme Disease Vaccine Market
• 9.6 Chinese Lyme Disease Vaccine Market
• 9.7 South Korean Lyme Disease Vaccine Market
• 9.8 Indonesian Lyme Disease Vaccine Market

10. ROW Lyme Disease Vaccine Market

• 10.1 Overview
• 10.2 ROW Lyme Disease Vaccine Market by Technology
• 10.3 ROW Lyme Disease Vaccine Market by End Use
• 10.4 Middle Eastern Lyme Disease Vaccine Market
• 10.5 South American Lyme Disease Vaccine Market
• 10.6 African Lyme Disease Vaccine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Technology
  • 12.2.2 Growth Opportunities by End Use
• 12.3 Emerging Trends in the Global Lyme Disease Vaccine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 T2 Biosystems
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bio-Rad Laboratories
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Oxford Immunotec USA
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 ROCHE DIAGNOSTICS INTERNATIONAL LTD
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Abbott
  • Company Overview
  • Lyme Disease Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us